-
Product Insights
Innovations in 25-OH Vitamin D Tests – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in 25-OH Vitamin D Tests - Global Pipeline Summary" provides comprehensive information about the 25-OH Vitamin D Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The 25-OH Vitamin D Tests report provides key information and data related to: Extensive coverage of the 25-OH Vitamin D Tests under development Review details of major pipeline products which include product description, licensing and collaboration...
-
Product Insights
NewNKG2 D Type II Integral Membrane Protein – Drugs In Development, 2024
The NKG2 D Type II Integral Membrane Protein pipeline drugs market research report outlays comprehensive information on the NKG2 D Type II Integral Membrane Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Solid Tumor, and Non-Small Cell Lung Cancer. It also reviews key players involved in NKG2 D Type II Integral...
-
Product Insights
NewComplement Factor D – Drugs In Development, 2024
The Complement Factor D pipeline drugs market research report outlays comprehensive information on the Complement Factor D targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genito Urinary System, Ophthalmology, and Hematological Disorders which include indications of Alzheimer's Disease, Glomerulonephritis, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Geographic Atrophy, Age Related Macular Degeneration, and Paroxysmal...
-
Product Insights
NewFAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase – Drugs In Development, 2024
The FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase pipeline drugs market research report outlays comprehensive information on the FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Infectious Disease which include indications of Tuberculosis, and Pulmonary Tuberculosis. It also reviews key players involved in FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase targeted therapeutics development with respective active and dormant or discontinued projects. Note:...
-
Product Insights
NewVascular Endothelial Growth Factor D – Drugs In Development, 2024
The Vascular Endothelial Growth Factor D pipeline drugs market research report outlays comprehensive information on the Vascular Endothelial Growth Factor D targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Ophthalmology, and Cardiovascular which include indications of Solid Tumor, Oncology, Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, and Refractory Angina. It also reviews key players...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – D-121 in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D-121 in Leishmaniasis (Kala-Azar) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. D-121 in Leishmaniasis (Kala-Azar) Drug Details: D-121 (Oleylphosphocholine) is under development...
-
Product Insights
NewSodium/Bile Acid Cotransporter – Drugs In Development, 2024
The Sodium/Bile Acid Cotransporter pipeline drugs market research report outlays comprehensive information on the Sodium/Bile Acid Cotransporter targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Infectious Disease, Gastrointestinal, Metabolic Disorders, and Undisclosed which include indications of Hepatitis B, Hepatitis D, Primary Sclerosing Cholangitis, Cholestasis, Unspecified Metabolic Disorders, and Unspecified. It also reviews key players involved in Sodium/Bile...
-
Product Insights
Akeso – Shanghai Global R&D Center – Shanghai
The Akeso – Shanghai Global R&D Center – Shanghai project involves the construction of a global research and development (R&D) center at the Zhangjiang Headquarters Park in Shanghai, China. Equip yourself with the essential tools needed to make informed and profitable decisions with our Akeso – Shanghai Global R&D Center – Shanghai report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding...
-
Company Insights
NewNestlé S.A. – Digital Transformation Strategies
Nestle Digital Transformation Strategies Overview Nestle has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and augmented reality to digitally transform its operations. The annual ICT spending of Nestle was estimated at $1.4 billion for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Nestlé S.A. (Nestlé) is a food and beverages company, offering more than 2,000 branded products across 190 countries. The company classifies its business operations...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABI-4334 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABI-4334 in Hepatitis B report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABI-4334 in Hepatitis B Drug Details: ABI-4334 is under development for...